There are “no current supply constraints” on Novo Nordisk’s insulin products, the organisation says
In a statement to its customers Novo wrote that “We know you are inundated with information. We recognise that you and your customers may have some questions regarding our medicine supply during this time”.
“We want to help provide clarity for you and your customers. We can assure you that we have no current supply constraints.”
The comments followed significant media coverage of medicines shortages, including in a piece on the 7.30 report earlier this week which discussed a mother of two young patients who was “struggling to have prescriptions filled”.
“The pharmacist came up, very apologetic but had said that there they are unable, they have no stock of NovoRapid and they did not know when the new stock was going to be coming in,” said Kristie Archer, whose 15-year-old son and 12-year-old daughter have type 1 diabetes.
“Currently, we are NOT experiencing any supply constraints in our global production, distribution or storage (warehouses),” wrote Novo Nordisk.
“We are well prepared for situations like this and have an inventory policy that serves long-term supply. This is important since our medicines are needed every day by patients all over the world.
“We appreciate you are experiencing increases in volumes.
“We strongly encourage you to enforce the guidance of the Department of Health which asks you to limit insulin dispensing to one month’s supply at the prescribed dose.
“We are in close contact with wholesalers and distributors to identify inventory management solutions and get stock to you as quickly as possible. We are also in close contact with Medicines Australia and the Australian Government with information about our supply levels.”